9.78 0.00 (0.00%)
After hours: 4:08PM EST
|Bid||9.61 x 1300|
|Ask||10.79 x 800|
|Day's Range||9.63 - 9.90|
|52 Week Range||7.11 - 14.62|
|Beta (3Y Monthly)||1.58|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 26, 2020 - Mar 2, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.04|
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Our research shows that most of the stocks that smart money likes historically generate strong […]
Yet another company wants to secure office space in Lake Nona, the fast-growing southeast Orlando suburb. Miami-based Pipeline Orlando LLC is in talks with Lake Nona developer Tavistock Development Co.
A land deal between Lake Nona's developer and a New Jersey biotech firm sets the stage for the latter company to bring new high-wage jobs and commercial development to southeast Orlando. Cranbury, New Jersey-based tech and biopharmaceutical company Amicus Therapeutics Inc. (Nasdaq: FOLD) bought 5.2 acres for $3.1 million, or roughly $596,153 an acre, in Lake Nona's 650-acre Medical City, according to Orange County records. Orlando-based Tavistock Development Co.'s Lake Nona Land Co. LLC was the seller.
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 25.00% and 1.47%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
3Q19 Galafold® (migalastat) Revenue of $48.8M and 1,000+ Patients on Therapy Reflects Continued Strong Global Uptake Reiterating Upwardly Revised FY19 Revenue.
PCTEL's (PCTI) third-quarter performance is likely have benefited from the demand for 5G scanning receivers and Industrial IoT antenna project wins.
Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the third quarter driven by clinical studies on its lead pipeline candidate, Zygel.
Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRANBURY, N.J., Oct. 30, 2019 -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, November 11,.
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]
Amicus Therapeutics (FOLD) today announced additional positive interim results from its CLN6 Batten disease gene therapy program licensed from the Abigail Wexner Research Institute (AWRI) at Nationwide Children’s Hospital. The results are featured in a poster presentation at the 48th Annual Meeting of the Child Neurology Society to be held October 23-26, 2019 in Charlotte, NC.
Amicus Therapeutics (FOLD) today announced preliminary unaudited revenue for the third quarter of 2019 in advance of its Analyst Day, to be held today, October 10, 2019, in New York City at 8:30 a.m. Today’s Analyst Day will highlight the financial strength and outlook of the Company in addition to recent progress and updates related to its early- and late-stage rare disease portfolio, including a late-stage biologic AT-GAA with breakthrough therapy designation (BTD) for Pompe disease, a clinical-stage intrathecal AAV gene therapy with positive interim results in CLN6 Batten disease, and a robust gene therapy pipeline. The live event will be audio webcasted simultaneously and accessible via the Investors section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/events-and-presentations, and will be archived for 90 days.
Amicus Therapeutics (FOLD) today announced additional positive results from a global Phase 1/2 clinical study (ATB200-02) to investigate AT-GAA in adult patients with Pompe disease, an inherited lysosomal storage disorder caused by an enzyme deficiency that leads to accumulation of glycogen (disease substrate) in cells. The U.S. Food and Drug Administration (FDA) previously granted Breakthrough Therapy Designation (“BTD”) to AT-GAA for the treatment of late onset Pompe disease based on clinical efficacy results this Phase 1/2 clinical study, including improvements in six-minute walk distance in late onset Pompe patients and comparison to natural history of treated patients.